INTRODUCTION {#s1}
============

Cancer is a substantial public health burden worldwide and is the second leading cause of death in the United States. An estimated 1,688,780 new cancer cases and 600,920 cancer deaths will occur in the United States this year \[[@R1]\]. Approximately 14 million new cancer cases occurred worldwide in 2012, and by 2025, global cancer incidence is predicted to rise to 20 million new cases annually \[[@R2]\]. Although there are many cancer risk factors, genetic abnormalities play crucial roles in carcinogenesis \[[@R3]--[@R6]\].

Apoptosis is a control mechanism to prevent over-proliferation in normal cells \[[@R7]\], and apoptosis pathway aberrations are implicated in cancer development \[[@R8]\]. Caspases are the main regulatory enzymes in the apoptosis pathway \[[@R9]\]. Caspase 8 mediates the extrinsic apoptosis pathway \[[@R10], [@R11]\]. Human *CASP8* is located on chromosome 2q33∼q34, has 11 exons \[[@R12]\], and is highly polymorphic with more than 474 single nucleotide polymorphisms (SNPs) according to the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>). The *CASP8* -652 6N ins/del polymorphism (rs3834129) is a six-nucleotide insertion/deletion variant located in the *CASP8* promoter region \[[@R13]\], and leads to decreased *CASP8* expression. Impaired caspase 8 function reduces T lymphocyte "activation-induced cell death" (AICD) activity, which is important in immune surveillance of cancer cells \[[@R13]\].

Extensive epidemiological studies have assessed the association between the *CASP8* -652 6N ins/del polymorphism and cancer risk. However, these studies have not produced conclusive results. The most recent previous meta-analysis of this association, conducted in 2014, assessed a relatively small number of studies. We performed this meta-analysis with a larger sample size to more precisely describe the association of interest.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Our study selection workflow is shown in Figure [1](#F1){ref-type="fig"}. Our systematic computer-based search initially identified 108 potentially relevant articles. After scanning titles and abstracts, 67 articles about unrelated topics were excluded. We further excluded 12 articles: eight were meta-analyses \[[@R14]--[@R21]\], three were case only studies \[[@R22]--[@R24]\], and one deviated from HWE \[[@R25]\]. Articles incorporating several ethnic groups or cancer types were separated into corresponding independent studies. In total, our analysis included datasets from 33 articles with 49 studies \[[@R13], [@R26]--[@R57]\].

![Flow diagram of the study selection process](oncotarget-08-56780-g001){#F1}

Characteristics for 33,494 cases and 36,397 controls are summarized in Table [1](#T1){ref-type="table"}. Of the included studies, 12 were conducted on colorectal cancer, nine on other cancers, eight on breast cancer, three on esophageal cancer, three on renal cell carcinoma, and two on lung cancer, cervical cancer, prostate cancer, bladder cancer, lymphoma cancer, and gastric cancer, respectively. Twenty-seven studies were conducted in Asians, 20 in Caucasians, one in Africans, and one in mixed populations. Twenty-four studies were of population-based design, 22 studies were of hospital-based design, and three did not mention study design in the original data. We also classified the studies as either low quality (25 studies) or high quality (24 studies) by quality score.

###### Characteristics of studies included in the meta-analysis

  Author last name   Year   Cancer type   Country        Ethnicity   Design   Genotype method   Case   Control   MAF    HWE    Score                                       
  ------------------ ------ ------------- -------------- ----------- -------- ----------------- ------ --------- ------ ------ ------- ------ ------ ------ ------ ------- ----
  Sun                2007   Lung          China          Asian       PB       PCR-RFLP          756    348       45     1149   640     407    64     1111   0.24   0.947   11
  Sun                2007   Esophagus     China          Asian       PB       PCR-RFLP          652    328       38     1018   543     338    56     937    0.24   0.724   11
  Sun                2007   Gastric       China          Asian       PB       PCR-RFLP          262    142       16     420    233     152    25     410    0.25   0.975   11
  Sun                2007   Colorectal    China          Asian       PB       PCR-RFLP          605    280       33     918    528     304    58     890    0.24   0.116   11
  Sun                2007   Breast        China          Asian       PB       PCR-RFLP          699    371       49     1119   513     419    72     1004   0.28   0.279   11
  Sun                2007   Cervical      China          Asian       PB       PCR-RFLP          199    102       13     314    314     211    42     567    0.26   0.428   10
  Yang               2008   Pancreatic    China          Asian       PB       PCR-RFLP          268    111       18     397    521     323    63     907    0.25   0.185   13
  Pittman            2008   Colorectal    England        Caucasian   PB       AS-PCR            995    1897      987    3879   892     1872   897    3661   0.50   0.170   9
  Frank              2008   Breast        Germany        Caucasian   HB       Fluorescent       298    535       221    1054   270     506    263    1039   0.50   0.403   7
  Frank              2008   Breast        England        Caucasian   PB       Fluorescent       235    541       251    1027   245     608    321    1174   0.53   0.169   10
  Frank              2008   Breast        Germany        Caucasian   PB       Fluorescent       280    509       222    1011   285     492    229    1006   0.47   0.550   9
  Frank              2008   Breast        England        Caucasian   PB       Fluorescent       1133   2115      1050   4298   1149    2263   1062   4474   0.49   0.422   8
  Cybulski           2008   Breast        Poland         Caucasian   PB       AS-PCR            178    314       126    618    274     499    192    965    0.46   0.195   6
  Cybulski           2008   Prostate      Poland         Caucasian   PB       AS-PCR            139    236       110    485    274     499    192    965    0.46   0.195   6
  Li                 2008   Melanoma      USA            Caucasian   HB       PCR               243    385       177    805    207     440    188    835    0.49   0.116   11
  Wang               2009   Bladder       China          Asian       HB       PCR-RFLP          238    115       12     365    205     138    25     368    0.26   0.786   10
  Gangwar            2009   Bladder       India          Asian       HB       PCR-RFLP          121    84        7      212    133     101    16     250    0.27   0.584   9
  De Vecchi          2009   Breast        Italy          Caucasian   PB       PCR-RFLP          162    301       117    580    106     206    94     406    0.49   0.752   7
  Zhu                2010   RCC           China          Asian       HB       PCR-RFLP          226    119       8      353    205     139    21     365    0.25   0.686   11
  Srivastava         2010   Gallbladder   India          Asian       PB       PCR-RFLP          147    69        12     228    122     84     24     230    0.29   0.103   11
  Liu                2010   Colorectal    China          Asian       PB       PCR-RFLP          233    116       21     370    528     278    32     838    0.20   0.538   13
  Li                 2010   HNSCC         USA            Caucasian   HB       PCR--RFLP         311    456       256    1023   257     542    253    1052   0.50   0.324   10
  Xiao               2011   Lymphoma      China          Asian       NM       PCR-PAGE          43     17        4      64     89      38     6      133    0.19   0.460   3
  Xiao               2011   Lymphoma      China          Asian       NM       PCR-PAGE          49     23        3      75     63      40     4      107    0.22   0.442   3
  Umar               2011   Esophageal    India          Asian       PB       PCR               139    103       17     259    138     93     28     259    0.29   0.046   11
  Theodoropoulos     2011   Colorectal    Greece         Caucasian   HB       RFLP-PCR          103    201       98     402    120     254    106    480    0.49   0.194   9
  Malik              2011   Esophageal    India          Asian       HB       RFLP-PCR          68     59        8      135    96      75     24     195    0.32   0.127   8
  Malik              2011   Gastric       India          Asian       HB       RFLP-PCR          59     44        5      108    96      75     24     195    0.32   0.127   8
  Ma                 2011   Ovarian       China          Asian       HB       MassARRAY         128    87        3      218    138     122    25     285    0.30   0.789   8
  Liamarkopoulos     2011   Gastric       Greece         Caucasian   HB       PCR-RFLP          35     42        11     88     120     254    106    480    0.49   0.194   7
  Hart               2011   Lung          Norway         Caucasian   PB       TaqMan            125    210       101    436    106     209    118    433    0.51   0.481   10
  Chatterjee         2011   Cervical      South Africa   African     HB       PCR-RFLP          18     63        25     106    43      129    85     257    0.58   0.614   6
  Fu                 2011   Prostate      China          Asian       HB       PCR-RFLP          257    132       17     406    211     159    38     408    0.29   0.315   10
  Wang               2012   RCC           China          Asian       HB       PCR-RFLP          192    101       7      300    168     114    18     300    0.25   0.817   10
  Wang               2012   PTC           China          Asian       HB       PCR--RFLP         65     45        8      118    106     92     15     213    0.29   0.408   7
  Tong               2012   ALL           China          Asian       HB       PCR-RFLP          217    113       31     361    338     153    28     519    0.20   0.057   10
  Hashemi            2012   Breast        Iran           Asian       HB       AS-PCR            113    107       16     236    79      91     33     203    0.39   0.434   6
  George             2012   Prostate      India          Asian       HB       PCR-RFLP          84     69        12     165    116     83     6      205    0.23   0.050   9
  Xiao               2013   Colorectal    China          Asian       HB       PCR-PAGE          187    107       11     305    212     115    15     342    0.21   0.905   7
  Wu                 2013   Colorectal    China          Asian       HB       PCR-SSCP          284    152       15     451    358     244    29     631    0.24   0.119   11
  De Martino         2013   RCC           Austria        Caucasian   HB       PCR-RFLP          72     138       40     250    53      129    68     250    0.53   0.572   9
  Pardini            2014   Colorectal    Spain          Caucasian   PB       Taqman            500    996       482    1978   425     802    420    1647   0.50   0.290   11
  Pardini            2014   Colorectal    Italy          Caucasian   PB       Taqman            195    285       137    617    783     1230   538    2551   0.45   0.178   9
  Pardini            2014   Colorectal    USA            Caucasian   PB       Taqman            237    514       259    1010   383     794    403    1580   0.51   0.835   9
  Pardini            2014   Colorectal    England        Caucasian   PB       Taqman            410    825       341    1576   165     393    209    767    0.53   0.436   11
  Pardini            2014   Colorectal    Czech          Caucasian   PB       Taqman            239    479       249    967    169     326    177    672    0.51   0.443   10
  Pardini            2014   Colorectal    Netherlands    Caucasian   PB       Taqman            169    282       134    585    106     177    76     359    0.46   0.895   8
  Tang               2015   OSCC          China          Asian       HB       PCR-RFLP          328    159       18     505    276     197    34     507    0.26   0.885   10
  Carvalho           2015   ALL           Brazil         Mixed       NM       PCR               23     81        26     130    47      53     25     125    0.41   0.163   4

MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium; OSCC: oral squamous cell carcinoma; PTC: papillary thyroid carcinoma; RCC: renal cell carcinoma; HNSCC: head and neck squamous cell carcinoma; ALL: acute lymphocytic leukemia; PB: population based; HB: hospital based; NM: not mentioned; PCR-PAGE: polymerase chain reaction-polyacrylamide gel electrophoresis; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; AS-PCR: allele-specific polymerase chain reaction.

Quantitative analysis {#s2_2}
---------------------

Overall meta-analysis information is shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. In the pooled analysis, the *CASP8* -652 6N ins/del polymorphism was associated with reduced overall cancer risk in all five genetic models (homozygous: DD vs. II: odds ratio (OR)=0.76, 95% confidence interval (CI)=0.69--0.84; heterozygous: ID vs. II: OR=0.87, 95% CI=0.83--0.92; recessive: DD vs. ID/II: OR=0.82, 95% CI=0.75--0.89; dominant: ID/DD vs. II: OR=0.85, 95% CI=0.80--0.90; and allele: D vs. I: OR=0.87, 95% CI=0.83--0.91.

###### Meta-analysis of the association between the *CASP8* -652 6N ins/del polymorphism and overall cancer risk

  Variables           No. of studies   Sample size   Homozygous             Heterozygous   Recessive              Dominant   Allele                                                                                   
  ------------------- ---------------- ------------- ---------------------- -------------- ---------------------- ---------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  All                 49               33494/36397   **0.76 (0.69-0.84)**   \<0.001        **0.87 (0.83-0.92)**   \<0.001    **0.82 (0.75-0.89)**   \<0.001   **0.85 (0.80-0.90)**   \<0.001   **0.87 (0.83-0.91)**   \<0.001
  Cancer type                                                                                                                                                                                                         
   Colorectal         12               13058/14418   0.93 (0.82-1.05)       0.018          **0.94 (0.88-0.99)**   0.529      0.96 (0.87-1.06)       0.019     **0.93 (0.87-1.00)**   0.190     0.96 (0.90-1.01)       0.012
   Breast             8                9943/10271    **0.80 (0.67-0.96)**   0.001          **0.90 (0.81-1.01)**   0.018      **0.85 (0.74-0.99)**   0.002     **0.87 (0.77-0.99)**   0.002     **0.89 (0.80-0.98)**   \<0.001
   Esophageal         3                1412/1196     **0.56 (0.40-0.78)**   0.901          0.93 (0.74-1.17)       0.206      **0.58 (0.42-0.79)**   0.812     **0.83 (0.71-0.97)**   0.385     **0.81 (0.72-0.92)**   0.712
   RCC                3                903/915       **0.39 (0.26-0.59)**   0.852          **0.78 (0.64-0.95)**   0.998      **0.46 (0.32-0.66)**   0.732     **0.71 (0.58-0.86)**   0.949     **0.70 (0.61-0.82)**   0.966
   Lung               2                1585/1544     **0.66 (0.51-0.87)**   0.473          **0.75 (0.64-0.88)**   0.385      **0.75 (0.59-0.95)**   0.458     **0.73 (0.63-0.85)**   0.453     **0.78 (0.69-0.87)**   0.273
   Cervical           2                420/824       **0.58 (0.36-0.93)**   0.456          0.86 (0.59-1.25)       0.230      **0.59 (0.39-0.88)**   0.728     **0.76 (0.59-0.98)**   0.355     **0.76 (0.63-0.92)**   0.556
   Prostate           2                650/205       1.54 (0.67-3.55)       0.100          0.99 (0.79-1.23)       0.411      1.50 (0.74-3.07)       0.135     1.05 (0.85-1.29)       0.321     1.11 (0.93-1.33)       0.255
   Bladder            2                577/618       **0.44 (0.25-0.77)**   0.799          0.79 (0.62-1.01)       0.334      **0.48 (0.27-0.84)**   0.907     **0.74 (0.59-0.93)**   0.317     **0.74 (0.61-0.90)**   0.338
   Lymphoma           2                139/240       1.19 (0.44-3.23)       0.729          0.82 (0.52-1.31)       0.635      1.26 (0.47-3.39)       0.789     0.86 (0.56-1.34)       0.559     0.93 (0.64-1.35)       0.535
   Gastric            2                196/675       **0.35 (0.19-0.63)**   0.939          0.74 (0.44-1.23)       0.145      **0.45 (0.26-0.78)**   0.538     0.64 (0.40-1.01)       0.171     **0.66 (0.51-0.84)**   0.487
   ALL                2                491/644       **1.85 (1.20-2.87)**   0.655          1.83 (0.69-4.85)       0.004      1.32 (0.81-2.14)       0.228     1.79 (0.81-3.97)       0.014     **1.33 (1.10-1.61)**   0.443
   Others             9                4120/4847     **0.57 (0.43-0.75**)   0.009          **0.72 (0.65-0.79)**   0.976      **0.65 (0.49-0.88)**   0.001     **0.70 (0.64-0.77)**   0.855     **0.75 (0.68-0.84)**   0.013
  Ethnicity                                                                                                                                                                                                           
   Asian              27               10569/11219   **0.58 (0.48-0.70)**   \<0.001        **0.80 (0.75-0.85)**   0.231      **0.62 (0.52-0.74)**   0.002     **0.77 (0.72-0.83)**   0.016     **0.79 (0.73-0.84)**   \<0.001
   Caucasian          20               22689/24796   **0.90 (0.83-0.98)**   0.006          **0.92 (0.88-0.97)**   0.225      0.95 (0.89-1.02)       0.007     **0.92 (0.87-0.97**)   0.079     **0.95 (0.91-0.99)**   0.008
   African            1                106/257       0.70 (0.35-1.43)       /              1.17 (0.62-2.19)       /          0.63 (0.37-1.05)       /         0.98 (0.54-1.80)       /         0.82 (0.60-1.13)       /
   Mixed              1                130/125       **2.13 (1.01-4.46)**   /              **3.12 (1.70-5.73)**   /          1.00 (0.54-1.85)       /         **2.80 (1.57-5.00)**   /         **1.50 (1.05-2.12)**   /
  Source of control                                                                                                                                                                                                   
   PB                 24               25259/26848   **0.83 (0.75-0.92)**   \<0.001        **0.89 (0.84-0.94)**   0.008      **0.89 (0.82-0.96)**   \<0.001   **0.87 (0.81-0.93)**   \<0.001   **0.89 (0.85-0.95)**   \<0.001
   HB                 22               7966/9184     **0.61 (0.49-0.75)**   \<0.001        **0.83 (0.77-0.89)**   0.213      **0.67 (0.55-0.82)**   \<0.001   **0.79 (0.73-0.87)**   0.024     **0.81 (0.75-0.88)**   \<0.001
   NM                 3                269/365       1.73 (0.95-3.14)       0.619          1.30 (0.53-3.20)       0.003      1.07 (0.63-1.80)       0.896     1.29 (0.58-2.88)       0.005     1.14 (0.79-1.64)       0.156
  Quality score                                                                                                                                                                                                       
   \>9                24               16745/16831   **0.67 (0.58-0.77)**   \<0.001        **0.81 (0.76-0.87)**   0.008      **0.75 (0.66-0.85)**   \<0.001   **0.78 (0.73-0.84)**   \<0.001   **0.81 (0.76-0.87)**   \<0.001
   ≤9                 25               16749/19566   **0.87 (0.77-0.99)**   \<0.001        0.95 (0.90-1.01)       0.289      **0.90 (0.81-1.00)**   \<0.001   **0.94 (0.88-1.00)**   0.048     **0.94 (0.90-0.99)**   \<0.001

Values were in bold, if the 95% CI excluded 1 or *P*\<0.05.

Het: heterogeneity; RCC: renal cell carcinoma; ALL: acute lymphocytic leukemia; HB: hospital based; PB: population based; NM: not mentioned.

![Forest plot of the association between the *CASP8* -652 6N ins/del polymorphism and cancer risk via the homozygous model\
The OR and 95% CI for each study are plotted as a box and horizontal line. ◊, pooled ORs and the corresponding 95% CIs.](oncotarget-08-56780-g002){#F2}

In cancer type stratification analysis, the *CASP8* -652 6N ins/del polymorphism decreased risk for colorectal cancer, breast cancer, esophageal cancer, renal cell carcinoma, lung cancer, cervical cancer, bladder cancer, gastric cancer, and other cancers. However, acute lymphocytic leukemia risk was increased (DD vs. II: OR=1.85, 95% CI=1.20--2.87; and D vs. I: OR=1.33, 95% CI=1.10--1.61). We observed no correlations between the *CASP8* -652 6N ins/del polymorphism and prostate cancer or lymphoma.

Stratification analysis by ethnicity revealed a decreased cancer risk for Asians (DD vs. II: OR=0.58, 95% CI=0.48--0.70) and Caucasians (DD vs. II: OR=0.90, 95% CI=0.83--0.98), and an increased risk in mixed populations (DD vs. II: OR=2.13, 95% CI=1.01--4.46). We also found that the *CASP8* -652 6N ins/del polymorphism decreased cancer risk in population-based (DD vs. II: OR=0.83, 95% CI=0.75--0.92) and hospital-based groups (DD vs. II: OR=0.61, 95% CI=0.49--0.75). Similarly, the *CASP8* -652 6N ins/del polymorphism was associated with decreased cancer risk in both the high quality (DD vs. II: OR=0.67, 95% CI=0.58--0.77) and low quality study groups (DD vs. II: OR=0.87, 95% CI=0.77--0.99).

Heterogeneity and sensitivity analysis {#s2_3}
--------------------------------------

Heterogeneity was observed in all five genetic models (*P*\<0.001, Q test). Therefore, the random-effect model was adopted to generate ORs and 95% CIs. We also conducted a sequential leave-one-out sensitivity analysis to evaluate the impact of a single study on the pooled estimates. Omission of no single study influenced the pooled ORs, indicating the statistical robustness of this meta-analysis (data not shown).

Publication bias {#s2_4}
----------------

Begg\'s funnel plot shapes did not suggest any obvious asymmetry (Figure [3](#F3){ref-type="fig"}). Egger\'s test results (DD vs. II: t=-4.17, *P*\<0.001; ID vs. II: t=-0.12, *P*=0.905; DD vs. ID/II: t=-1.15, *P*=0.257; ID/DD vs. II: t=-1.09, *P*=0.281; and D vs. I: t=-3.33, *P*=0.002) suggested that publication bias existed in the homozygote and allele models.

![Funnel plot analysis to detect publication bias for the *CASP8* -652 6N ins/del polymorphism via the homozygous model\
Each point represents a separate study for the indicated association.](oncotarget-08-56780-g003){#F3}

Trial sequential analysis {#s2_5}
-------------------------

To minimize random errors and strengthen the robustness of our conclusions, we performed trial sequential analysis (TSA) (Figure [4](#F4){ref-type="fig"}). The cumulative Z-curve crossed the trial sequential monitoring boundary before the required information size was reached, suggesting that our study conclusion was convincing and no additional evidence was needed to verify said conclusion.

![Trial sequential analysis for the *CASP8* -652 6N ins/del polymorphism via the allele contrast model](oncotarget-08-56780-g004){#F4}

DISCUSSION {#s3}
==========

The present meta-analysis comprehensively evaluated the relationship between the *CASP8* -652 6N ins/del polymorphism and cancer risk across 49 studies (33,494 cases and 36,397 controls). The *CASP8* -652 6N ins/del polymorphism was associated with decreased cancer risk in all five genetic models, and in the following subgroups: colorectal cancer, breast cancer, esophageal cancer, renal cell carcinoma, lung cancer, cervical cancer, bladder cancer, gastric cancer, other cancers, Asian, Caucasian, mixed population, population-based controls, hospital-based controls, high quality score, and low quality score.

Human immune cells play critical roles in eliminating potentially malignant cells \[[@R58]\]. Caspase 8 protein (encoded by *CASP8*) maintains immune cells by mediating the activation-apoptosis balance \[[@R59]\]. Low caspase 8 expression or functional aberrations may decrease T lymphocyte apoptotic reactivity \[[@R13]\]. The *CASP8* -652 6N del variant inactivates the transcription factor stimulatory protein 1 binding site, decreasing *CASP8* transcription \[[@R13]\]. Thus, this variant may affect cancer susceptibility by influencing immune surveillance.

The first case-control study of the *CASP8* -652 6N del variant-cancer association, with 4,995 cases and 4,972 controls, was conducted by Sun, *et al*. in 2007 \[[@R13]\]. The authors found that the *CASP8* -652 6N deletion allele decreased susceptibility to lung, colorectal, esophageal, breast, cervical, and gastric cancers. Biochemical assays illustrated that this variant might decrease apoptotic reactivity in cancer cell-stimulated T lymphocytes. However, Umar, *et al*. did not detect any association between the *CASP8* -652 6N polymorphism and esophageal squamous cell carcinoma (ESCC) risk in 259 patients and 259 healthy controls in an Indian population \[[@R45]\]. Several meta-analyses have attempted to address these contradictory conclusions. A 2012 meta-analysis by Chen, *et al*., including 19 case-control studies with 23,172 cases and 26,532 controls, associated the del allele, ins/del genotype, and del allele carriers with reduced overall cancer risk \[[@R16]\]. Similarly, in a meta-analysis incorporating 11 reports with 27,459 cases and 31,614 controls, Yin, *et al*. associated the *CASP8* -652 5N del polymorphism with reduced overall cancer risk via homozygous, dominant, and recessive models \[[@R15]\]. In 2014, breast cancer- and colorectal cancer-specific meta-analyses \[[@R19], [@R20]\] concluded that the *CASP8* -652 6N del polymorphism reduced cancer risk. However, no association was observed between this polymorphism and prostate cancer susceptibility in a meta-analysis by Zhang, *et al*. \[[@R21]\].

To provide a more robust clarification, our meta-analysis included all eligible studies published in either the English or Chinese language. In agreement with the four previously published meta-analyses, we found that the *CASP8* -652 6N ins/del polymorphism was associated with reduced overall cancer risk. In subgroup analyses, the polymorphism was associated with reduced risk of colorectal cancer, breast cancer, esophageal cancer, renal cell carcinoma, lung cancer, cervical cancer, bladder cancer, gastric cancer, and other cancers, but not prostate cancer or lymphoma. A prostate cancer-specific meta-analysis also failed to detect a significant association. This may be attributed to cancer-specific inherent heterogeneity \[[@R60], [@R61]\]. Additionally, we observed an association with decreased cancer risk among Asians and Caucasians, but not Africans or mixed ethnicity populations. However, the limited number of studies in Africans and mixed ethnicity population may account for this finding, and *CASP8* -652 6N ins/del polymorphism allelic distributions might vary geographically and ethnically.

Our meta-analysis of the association between the *CASP8* -652 6N ins/del polymorphism and cancer risk is by far the largest such meta-analysis with the greatest statistical power published thus far. We conducted subgroup analyses to provide a more precise, cancer type-specific conclusion, and we assessed studies in both Chinese and English to minimize selection bias. However, our study had certain limitations. First, for some types of cancers, the calculated association was not robust enough due to limited numbers of original studies. Second, only one *CASP8* genetic variant was considered, and confounding factors, such as other genetic mutations and environmental exposures, also influence cancer susceptibility. Third, the observed between-study heterogeneity may reduce the validity of our conclusions. Finally, publication bias, language bias, or selection bias might lead to false positive or negative findings.

The present work robustly concludes that the *CASP8* -652 6N ins/del polymorphism is associated with reduced overall cancer risk. Refined studies with larger sample sizes, especially for certain cancer types and ethnic groups, are needed to fully validate this relationship.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We conducted a literature search in PubMed and EMBASE using the following combined terms: '*Caspase 8*' or '*CASP8*' and 'polymorphism' or 'polymorphisms' or 'single nucleotide polymorphism' or 'SNP' or 'variant' and 'cancer' or 'tumor' or 'carcinoma' or 'carcinogenesis' or 'neoplasm'. We also searched studies written in Chinese from two databases, WANFANG and CNKI. We searched for articles published through February 2017 without imposing language limitations. Relevant references were also collected from retrieved articles. Only the largest or the most recent study was retained if studies contained overlapping data.

Inclusion/exclusion criteria {#s4_2}
----------------------------

Studies included in our analysis met the following criteria: (1) evaluated *CASP8* -652 6N ins/del polymorphism with respect to cancer risk; (2) case-control design; (3) sufficient information to extract genotype frequencies for all subjects; (4) genotype frequency of controls consistent with Hardy-Weinberg equilibrium (HWE); (5) publication language was English or Chinese. Criteria for exclusion included: (1) abstract only, review, or meta-analysis; (2) case only studies; (3) no detailed genotyping data provided; (4) repeated publication.

Data extraction {#s4_3}
---------------

Two authors (Jiarong Cai and Qingjian Ye) independently identified all eligible studies, and extracted data was included in the meta-analysis following consensus. The following items were recorded from each study: first author\'s name, year of publication, country, patient ethnicity, cancer type, source of controls, genotyping method, and genotype distributions of cases and controls. If reports contained more than one ethnic group or cancer type, we separated them into different studies.

Trial sequential analysis {#s4_4}
-------------------------

After adopting a risk of 5% for type I errors and 30% for type II errors, the required information size (sample sizes from all included trials) was calculated. TSA monitoring boundaries were built based on required information size and risk for type I and type II errors. If the cumulative Z-curve crossed the TSA monitoring boundary before the required information size was reached (i.e. if a sufficiently small *P*-value was achieved), further trials were unnecessary.

Statistical analyses {#s4_5}
--------------------

We used the Chi-square test to ensure that all control genotype frequencies were in agreement with HWE. Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) obtained from case and control genotype frequencies were used to assess the strength of association between the *CASP8* -652 6N ins/del polymorphism and cancer risk. Pooled ORs were calculated for the following five genetic models: homozygote model (DD vs. II), heterozygote model (ID vs. II), recessive model (DD vs. ID/II), dominant model (ID/DD vs. II), and allele model (D vs. I). The Cochran\'s Chi-square-based Q-test and the inconsistency index (I^2^ statistics) were adopted to assess heterogeneity between study results. I^2^\<50% or *P*\>0.10 indicates heterogeneity. The fixed-effects model (Mantel-Haenszel method) was used to estimate the pooled OR if no heterogeneity existed (I^2^\<50% or *P*\>0.10). Otherwise, the random-effects model (DerSimonian and Laird method) was applied. Quality assessment for each study was performed using the quality assessment criteria described previously ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R62]--[@R65]\]. To decrease heterogeneity among studies, we conducted stratification analyses by ethnicity, cancer type, control source, and quality score. By adopting one-way sensitivity analysis, we recalculated the pooled ORs to assess the robustness of the results. We also conducted Begg\'s funnel plot and Egger\'s regression asymmetry test to examine potential publication bias \[[@R66]--[@R69]\]. STATA software v. 11.0 (Stata Corporation, College Station, TX) was used for statistical analyses \[[@R70]\]. *P*\<0.05 (two-sided) was considered statistically significant.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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